| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | PDMP | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |